ATC Group: P01BC02 Mefloquine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of P01BC02 in the ATC hierarchy

Level Code Title
1 P Antiparasitic products, insecticides and repellents
2 P01 Antiprotozoals
3 P01B Antimalarials
4 P01BC Methanolquinolines
5 P01BC02 Mefloquine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 g

Active ingredients in P01BC02

Active Ingredient Description
Mefloquine

Mefloquine acts on and destroys the asexual intraerythocytic forms of the human malaria parasites: Plasmodium falciparum, P. vivax. P. malariae and P. ovale. It is effective in the treatment and prophylaxis of malaria.

Related product monographs

Title Information Source Document Type  
LARIAM Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Japan (JP)

Malta (MT)

Netherlands (NL)

Singapore (SG)

South Africa (ZA)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.